DMU-212 against EGFR-mutant non-small cell lung cancer via AMPK/PI3K/Erk signaling pathway

DMU-212 against EGFR-mutant non-small cell lung cancer via AMPK/PI3K/Erk signaling pathway

Although some important advances have been achieved in clinical and diagnosis in the past few years, the management of non-small cell lung cancer (NSCLC) is ultimately dissatisfactory due to the low overall cure and survival rates. Epidermal growth factor (EGFR) has been recognized as a carcinogenic...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Xiao-Ping Zhao, Xiao-Li Zheng, Min Huang, Ya-Jia Xie, Xiao-Wen Nie, Ali Adnan Nasim, Xiao-Jun Yao, Xing-Xing Fan
Format:	Artykuł
Język:	English
Wydane:	Elsevier 2023-05-01
Seria:	Heliyon
Hasła przedmiotowe:	EGFR mutation NSCLC Lung cancer DMU-212 EGFR-AMPK pathway
Dostęp online:	http://www.sciencedirect.com/science/article/pii/S2405844023030190

Podobne zapisy

In Vivo Metabolite Profiling of DMU-212 in Apc<sup>Min/+</sup> Mice Using UHPLC-Q/Orbitrap/LTQ MS
od: Jing Li, i wsp.
Wydane: (2023-04-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
od: Meng-Xia Li, i wsp.
Wydane: (2017-04-01)

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
od: Hua Ye, i wsp.
Wydane: (2020-07-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
od: Li Liu, i wsp.
Wydane: (2021-10-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
od: Kejing Tang, i wsp.
Wydane: (2019-02-01)

EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)—A Podcast Discussion Between Patients and Oncologists
od: Stephen V. Liu, i wsp.
Wydane: (2023-09-01)

Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
od: Di Hu, i wsp.
Wydane: (2023-06-01)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
od: Chien-Chung Lin, i wsp.
Wydane: (2021-02-01)

EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
od: Jeng-Shiuan Tsai, i wsp.
Wydane: (2021-09-01)

Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
od: Chen Liao, i wsp.
Wydane: (2025-01-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
od: Jae Cheol Lee, i wsp.
Wydane: (2021-05-01)

Long term survival achieved through combination of almonertinib and pyrotinib in EGFR-mutant/HER2-amplified advanced NSCLC patient: a case report and literature review
od: Xin Pan, i wsp.
Wydane: (2024-08-01)

Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
od: Alexander Meisel
Wydane: (2020-03-01)

Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
od: Yongkang Bai, i wsp.
Wydane: (2023-04-01)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
od: Ling Li, i wsp.
Wydane: (2020-09-01)

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC
od: Shao J, i wsp.
Wydane: (2024-06-01)

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
od: William Tompkins, MD, i wsp.
Wydane: (2024-08-01)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
od: Kate S, i wsp.
Wydane: (2019-01-01)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
od: Yanjun Huang, i wsp.
Wydane: (2018-07-01)

First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations
od: Tia Cheunkarndee, BA, i wsp.
Wydane: (2024-06-01)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
od: Jinyao Zhang, i wsp.
Wydane: (2021-12-01)

Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer
od: Yen‐Ting Lin, i wsp.
Wydane: (2024-01-01)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
od: Antonio Passaro, i wsp.
Wydane: (2021-07-01)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
od: Helei Hou, i wsp.
Wydane: (2021-03-01)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
od: Xiaoyu Qian, i wsp.
Wydane: (2022-08-01)

Disease monitoring of epidermal growth factor receptor (EGFR)‐mutated non‐small‐cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNA
od: Yan Li, i wsp.
Wydane: (2022-08-01)

Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon EGFR Mutations
od: Christoforos Astaras, i wsp.
Wydane: (2020-03-01)

Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer
od: Vinh Thanh Tran, i wsp.
Wydane: (2020-08-01)

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
od: Anne C. Chiang, i wsp.
Wydane: (2020-04-01)

Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients
od: Obradovic Jasmina, i wsp.
Wydane: (2012-12-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
od: Alessandro Leonetti, i wsp.
Wydane: (2021-06-01)

Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR‐mutated non‐small‐cell lung cancer: A case report
od: Meng Zhang, i wsp.
Wydane: (2022-05-01)

A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms
od: Joel Rivera-Concepcion, i wsp.
Wydane: (2024-03-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
od: Meiyi XU, i wsp.
Wydane: (2023-02-01)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
od: Xue-Wu Wei, MD, i wsp.
Wydane: (2022-07-01)

Design, Synthesis and Evaluation of Novel Cyclopropanesulfonamide Derivatives for the Treatment of EGFRC797S Mutation in Non-Small Cell Lung Cancer
od: Wang M, i wsp.
Wydane: (2025-02-01)

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study
od: Yuankai Shi, i wsp.
Wydane: (2023-01-01)

Clinical Management in NSCLC Patients With EGFR Mutation After Osimertinib Progression With Unknown Resistance Mechanisms
od: Xin Liao, i wsp.
Wydane: (2024-10-01)

Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis
od: Haosheng Zheng, i wsp.
Wydane: (2024-01-01)

Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
od: Kaiwen Wang, PharmD, i wsp.
Wydane: (2023-08-01)